Research page
RTA
Retatrutide



Specification
| Name | RTA · Retatrutide |
|---|---|
| Catalog sizes | 10 mg, 15 mg, 20 mg |
| Adopted bacteriostatic water | 10 mg + 1.0 mL = 10 mg/mL · 15 mg + 1.5 mL = 10 mg/mL · 20 mg + 2.0 mL = 10 mg/mL · 25 mg + 2.5 mL = 10 mg/mL · 30 mg + 3.0 mL = 10 mg/mL |
Overview
RTA is the TRACE catalog name for retatrutide, an investigational peptide that engages three incretin receptors: GLP-1, GIP, and glucagon. It is not an approved medicine. This page summarizes published biology and the reconstitution figures TRACE has adopted. It does not state an amount for any person.
Mechanism under study
In models and in early clinical trials it is described as a triple agonist. GLP-1 receptor signaling has been studied in relation to satiety and glucose-dependent insulin secretion. GIP signaling has been studied as a complement to that response. Glucagon-receptor signaling has been studied in relation to energy expenditure and hepatic fat metabolism.
What published research has reported
A phase 2 trial, published in The New England Journal of Medicine in 2023, studied once-weekly retatrutide in adults with obesity and described weight reductions that varied with dose over 48 weeks. That trial is about an investigational compound, not an instruction for use.
Another phase 2 trial, published in The Lancet in 2023, studied retatrutide in adults with type 2 diabetes and compared glycemic control and weight with placebo and with an active comparator. TRACE does not reproduce the dose tables from those papers.
Composition and mass
The catalog offers 10 mg, 15 mg, and 20 mg vials. The adopted rule is a fixed concentration of 10 mg/mL. The 25 mg and 30 mg sizes are part of that same rule and are not in the current catalog.
Reconstitution
| mg | mL | mg/mL | |
|---|---|---|---|
| 10 | 1.0 | 10 | In the catalog |
| 15 | 1.5 | 10 | In the catalog |
| 20 | 2.0 | 10 | In the catalog |
| 25 | 2.5 | 10 | On the rule, not in the catalog |
| 30 | 3.0 | 10 | On the rule, not in the catalog |
Storage and handling
The lyophilized cake is kept cool, dry, and protected from light. After water is added, the vial is refrigerated at 2–8 °C, not frozen, and treated as material to use within 28 days.
Regulatory status
Retatrutide is an investigational compound and is not FDA-approved. This vial is not a drug, a supplement, or a food. The statements on this page have not been evaluated by the FDA.